ArticleHuman genomics2026
Global developmental delay and focal seizures in individuals with de novo truncating MACF1 variants.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMicrotubule and actin crosslinking factor 1 (MACF1) plays a critical role in cytoskeletal regulation. Pathogenic variants in MACF1 are associated with a heterogeneous range of phenotypes, including epilepsy, intellectual disability, developmental delay, brain malformations, and hypotonia. This study aims to report two novel MACF1 variants and further explore the genotype-phenotype correlations and pathogenic mechanisms of MACF1-related disorders.
resultsWe identified two Chinese patients with de novo heterozygous MACF1 variants. Patient 1 carried a frameshift variant (c.18699_18700del, p.V6234Dfs*2) in the spectrin repeats domain (SRD) and presented with global developmental delay. Patient 2 harbored a nonsense variant (c.19657 C > T, p.Q6533*), also located in the SRD. This patient exhibited focal seizures that were readily controlled with valproic acid and perampanel, along with borderline intelligence, oppositional behavior, and hyperactivity. A review of the literature indicated that variants linked to neuropsychiatric disorders tend to cluster within the SRD, likely acting through a loss-of-function (LoF) mechanism and as risk factors for these type of disorders. Furthermore, the two truncating MACF1 variants we reported most likely act through haploinsufficiency.
conclusionsOur findings broaden the phenotypic spectrum of MACF1-associated disorders and provide additional evidence for genotype-phenotype correlations. The results also support the role of haploinsufficiency as a possible pathogenic mechanism in de novo MACF1 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.